Healthtech Startups

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.

4 investors

Octagon Therapeutics is a biotech company developing new medicines for autoimmune diseases with unmet clinical need, based on scientific research from Harvard. It serves patients living with autoimmunity through its drug development programs.

4 investors

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.

4 investors

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments. It conducts formulation, process, and analytical development to advance drug candidates from early research through later development stages.

4 investors

OhmniLabs builds robots for healthcare, including an autonomous UV-C disinfection robot (OhmniClean), a mobile telehealth platform (OhmniCare) for providers to expand patient access in fields like nutrition and pharmacy, and telepresence robots. Its products target healthcare providers and disinfection services.

4 investors

OKKO Health develops smartphone and tablet apps that measure vision through games built on vision science, for use in clinical practice, scientific research, and drug and device R&D. The company captures home-monitoring data to build predictive algorithms that identify sight problems early and flag who needs professional eye care.

4 investors

Olive develops machine learning and signal processing technology with applications across education, mobility, and healthcare sectors. The company combines expertise in ML, signal processing, and biomedical engineering to deliver field-tested solutions.

4 investors

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs. The company builds integrated development and commercialization capabilities while partnering to advance programs addressing large indications.

4 investors

Ombre Lab offers at-home microbiome testing powered by AI, providing personalized microbiome reports and targeted probiotic recommendations based on DNA sequencing and proprietary bioinformatics. The company serves consumers seeking microbiome self-care through a direct-to-consumer model.

4 investors

OmniLife Health develops FlowHawk, a clinical workflow automation platform that helps care teams manage complex care pathways, with initial focus on organ transplant centers. The platform digitizes care conversations outside the EHR and facilitates communication and collaboration across hospital teams.

4 investors

One Codex provides microbiome sequencing data analysis and reporting software for academic labs, biotechnology companies, and clinical laboratories. The platform uses advanced algorithms and a curated database to analyze metagenomic samples with a web-based interface accessible to both bench scientists and computational biologists.

4 investors

Ophidion is a biotechnology company developing therapeutics based on the cholinergic system and lynx gene modulators, which regulate nicotinic acetylcholine receptors. Its drug discovery programs target neurological and related conditions, including an early small-molecule smoking cessation candidate and peptide/protein programs.

4 investors

Vivo Care provides remote patient monitoring and chronic care management software combined with nurse-led clinical support to help healthcare providers deliver care outside the clinic setting for patients with chronic conditions. The platform targets provider teams and practices seeking to improve patient outcomes, reduce healthcare costs, and generate new revenue streams.

4 investors

Opya provides early intervention ABA (applied behavior analysis) therapy for young children diagnosed with autism and their families. It operates as an accredited autism care provider in California.

4 investors

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space. It is backed by healthcare-focused investors and announced a Series D financing in October 2024.

4 investors

Orbis Diagnostics is developing a point-of-care diagnostics platform that produces blood test results from a single fingerstick of blood. The product targets clinical blood testing in the medical diagnostics field.

4 investors

Orbit Discovery provides peptide discovery solutions for pharmaceutical and biotechnology companies, serving both large pharmaceutical firms and smaller biotech enterprises.

4 investors

OrCam builds AI-powered handheld and wearable assistive devices, such as the MyEye and Read product lines, that read text aloud, describe surroundings, and recognize faces. The products serve blind, visually impaired, and low-vision users as well as people with reading challenges like dyslexia and ADHD.

4 investors

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.

4 investors

Orderly Health uses AI and machine learning to process provider roster updates and maintain a centralized provider directory, improving the accuracy and reliability of healthcare provider data. It serves healthcare providers, payers, and health technology companies for uses such as regulatory compliance, patient access, and market intelligence.

4 investors

Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases. The company works within the healthcare and pharmaceutical industry to address patient health challenges.

4 investors

Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.

4 investors

OSSIO develops OSSIOfiber, a bio-integrative bone fixation implant material made from natural mineral fibers that provides stability during healing and integrates fully into bone over 18-24 months, avoiding permanent metal hardware. The implants are used in orthopedic surgical procedures such as hammertoe and other bone-healing treatments.

4 investors

Ostro (Veeva Ostro) offers an AI-driven omnichannel engagement platform for biopharmaceutical, medical device, digital therapeutic, and diagnostics companies to deliver compliant, personalized content and experiences to healthcare providers and patients. Its solutions connect email, HCP sites, and patient sites for regulated pharmaceutical and healthcare marketing.

4 investors